Insufficient scRNA-seq data for expression of AMACR at single-cell level.
Insufficient scRNA-seq data for expression of AMACR at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1048.30 | 245 / 245 | 97% | 25.93 | 489 / 502 |
kidney | 100% | 6889.04 | 89 / 89 | 89% | 10.44 | 801 / 901 |
intestine | 100% | 1352.81 | 966 / 966 | 81% | 3.59 | 429 / 527 |
liver | 100% | 3412.81 | 226 / 226 | 80% | 4.92 | 325 / 406 |
stomach | 100% | 3041.94 | 359 / 359 | 74% | 3.77 | 212 / 286 |
bladder | 100% | 907.95 | 21 / 21 | 54% | 2.35 | 273 / 504 |
esophagus | 100% | 1027.92 | 1442 / 1445 | 41% | 0.85 | 75 / 183 |
lung | 97% | 546.72 | 563 / 578 | 40% | 0.79 | 463 / 1155 |
adrenal gland | 100% | 1567.40 | 258 / 258 | 37% | 0.56 | 86 / 230 |
skin | 99% | 722.20 | 1798 / 1809 | 29% | 0.54 | 139 / 472 |
breast | 99% | 585.02 | 453 / 459 | 29% | 0.42 | 319 / 1118 |
pancreas | 100% | 648.72 | 327 / 328 | 28% | 1.40 | 49 / 178 |
brain | 100% | 1029.05 | 2634 / 2642 | 27% | 0.35 | 191 / 705 |
uterus | 98% | 589.84 | 167 / 170 | 22% | 0.43 | 100 / 459 |
thymus | 100% | 645.97 | 651 / 653 | 20% | 0.32 | 119 / 605 |
ovary | 98% | 564.28 | 177 / 180 | 14% | 0.17 | 59 / 430 |
spleen | 100% | 474.67 | 240 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 630.49 | 1321 / 1335 | 0% | 0 | 0 / 0 |
adipose | 98% | 573.00 | 1182 / 1204 | 0% | 0 | 0 / 0 |
muscle | 94% | 575.44 | 757 / 803 | 0% | 0 | 0 / 0 |
heart | 88% | 453.28 | 759 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 65% | 347.00 | 604 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 35% | 0.60 | 28 / 80 |
tonsil | 0% | 0 | 0 / 0 | 11% | 0.12 | 5 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006699 | Biological process | bile acid biosynthetic process |
GO_0008206 | Biological process | bile acid metabolic process |
GO_0033540 | Biological process | fatty acid beta-oxidation using acyl-CoA oxidase |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005829 | Cellular component | cytosol |
GO_0005777 | Cellular component | peroxisome |
GO_0005782 | Cellular component | peroxisomal matrix |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0008111 | Molecular function | alpha-methylacyl-CoA racemase activity |
Gene name | AMACR |
Protein name | Alpha-methylacyl-CoA racemase (EC 5.1.99.4) (2-methylacyl-CoA racemase) Alpha-methylacyl-CoA racemase |
Synonyms | |
Description | FUNCTION: Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters . Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither 3-methyl-branched nor linear-chain acyl-CoAs . . |
Accessions | ENST00000335606.11 [Q9UHK6-1] Q9UHK6 D6RB81 ENST00000506639.5 [Q9UHK6-2] ENST00000502637.5 ENST00000382085.7 [Q9UHK6-5] ENST00000382072.6 [Q9UHK6-4] |